Just - Evotec Biologics

Amgen and other biopharma leaders are embracing continuous manufacturing. Why? It's transforming how they produce life-saving medicines. Dive into a real-world case study: A hybrid continuous manufacturing process achieved: - 80% reduction in process media and buffer usage - 15x more product per batch - 45x higher productivity ...all without increasing costs or needing more space! The key? Smartly repurposing existing facilities and optimizing production times. The Impact: Lower costs for antibody therapeutics mean wider access for patients in need. Read the full study and learn how you can leverage these groundbreaking innovations below! https://hubs.ly/Q02MTsK50 #BiotechInnovation #PharmaManufacturing #HealthcareRevolution

Read the August issue of our monthly newsletter for the latest updates and exciting developments in #continuousmanufacturing. Industry Round-Up: In a study published in the Journal of Pharmaceutical Sciences the authors discuss the advantages of decentralized manufacturing in small-scale production facilities. Read our key takeaways. News at Just - Evotec Biologics: Our new J.POD biologics manufacturing facility is set to open this September in Toulouse, France. Read the latest article discussing continuous biomanufacturing's arrival in Europe and our recent case study about how OncoResponse partnered with us to develop a continuous manufacturing process for their Phase I clinical trials. For full details, read our newsletter here- https://hubs.ly/Q02MSshb0

Step into the world of Evotec at CPhI Milan! Discover our tailored solutions and explore our API and drug product capabilities. Want to learn more about our API and drug product capabilities? Interested in our Just - Evotec Biologics development and #biomanufacturing services for #antibody & antibody-related therapeutics? Or perhaps our integrated continuous manufacturing platforms? And how about seeing our experts in action at our Verona site? Find all details here https://hubs.ly/Q02M2JWk0 - Don't wait to request a meeting or a site visit! #CPHI #drugdevelopment

Just – Evotec Biologics was thrilled to host a visit from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to its Seattle and J.POD® Redmond, WA (US) facilities. This visit was part of the Manufacturing Optimization Program effort to enhance the U.S. Government’s rapid response capabilities for biologics medical counter measures in response to emergency situations. Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DODs Manufacturing Optimization Program. Learn more here- https://hubs.ly/Q02M2X0Y0 #biologics #biomanufacturing #Seattle

At our new GMP #biomanufacturing facility in Toulouse, #France, we use cleanroom pods that house our extremely intensified processes to manufacture biologics. Not only do these pods give us great flexibility, but we can also easily add new pods to increase our manufacturing capacity when needed. Our colleagues Philip Boehme and Nick Hutchinson discuss how it works. #biologics #continuousbiomanufacturing

Only 1 month to go before our J.POD® Toulouse facility launches! J.POD Toulouse, France (EU) features our #continuousbiomanufacturing platform to produce therapeutic #antibody #biotherapeutics. The facility hosts a full complement of process development services and GMP manufacturing all under one roof. Read about how continuous manufacturing arrives in Europe here- https://hubs.ly/Q02LStPV0 Contact Us: [email protected] #biomanufacturing #Toulouse #France

Learn how OncoResponse partnered with Just-Evotec Biologics to develop a #ContinuousManufacturing process that would supply their Phase 1 clinical trials. Just-Evotec Biologics provided: - J. MD Molecular Design Services - Our J.CHO High Expression System - Process Development and Scale-Up - Phase 1 Clinical Manufacturing Read the case study here: https://hubs.ly/Q02LpHFF0 #researchneverstops #Oncology #JustEvotecBiologics

Huge News! If you want to learn how to adopt continuous purification processes, we’re giving away some of our top tips! Download this amazing resource from Michelle Najera, Megan McClure, Shahbaz Gardezi and Beth Larimore here: https://hubs.ly/Q02LpKWt0 Learn how: 1. Process intensification solutions for monoclonal antibodies, Fc-fusion proteins and bispecific antibodies ease liquid handling pain points. 2. Our J.CHO High Expression System is delivering perfusion permeate titers of over 2 g/L/d over 25 days. 3. Continuous capture chromatography significantly enhances resin utilization 4. Two tank virus inactivation steps can be developed with bench-scale models Presented at 'Recovery of Biological Products XX' and titled “Turning the crank using a hybrid continuous purification platform” this is one not to miss. #continuousbiomanufacturing #justevotecbiologics #researchneverstops

It makes no sense to take an unoptimized #bioprocess into commercial manufacturing. If you went through IND with a rough-and-ready fed-batch process, we recommend you convert that to continuous before your BLA submission. When exactly should you do that? We encourage partners to do that as early in the clinical life cycle as they can. Here’s why: • Material generated for pivotal studies will be comparable with that from commercial manufacturing. • You’ll gain maximum experience and data for your regulatory filings from your new optimize continuous manufacturing process. • It will give you the benefits of continuous biomanufacturing in late-stage clinical supply, such as agility, flexibility and low cost of goods. To learn more, visit our website here- https://hubs.ly/Q02LpjwF0 Contact us: [email protected]

Evotec SE today announced its financial results and corporate updates for the first half-year of 2024. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said, ““During my first few weeks at Evotec, I have been hugely impressed by the dedication of our world-class talent base, the quality of our leading-edge technology platforms, and the deep partnerships with top pharma and biotech. We are an R&D powerhouse. Our science, our partnerships, and our people are the core strengths on which we will continue to build." To read his full quote and to learn more, read the press release here- https://hubs.ly/Q02Ld6b-0 #ResearchNeverStops #TogetherForMedicinesThatMatter